This week, our attention turns to two pivotal biotech catalysts, especially the Phase 1 data presentation for Troculeucel (SNK01) in moderate Alzheimer's disease on November 16, 2026. With a 3% probability of approval, investors need to balance potential benefits against the significant unmet need in Alzheimer's treatment, a market projected to reach $40.5 billion this year. The stakes are high as these results could influence the future of NK cell therapies in an already crowded Alzheimer's field.
Troculeucel Phase 1: Biotech Catalysts Nov 16, 2026
The full biotech catalysts to watch
| Date | Ticker | Drug | Indication | Phase | PoA |
|---|---|---|---|---|---|
| 2026-11-16 | NKGN | troculeucel (SNK01) (+0% run-up) | Moderate Alzheimer's disease | Phase 1 | 3% |
| 2026-12-03 | EYPT | Bioerodible EYP-1901 (vorolanib intravitreal insert) (-89.8% run-up) | Wet AMD | Phase 3 | 18% |
| 2026-11-16 | PMN | PMN310 (PRECISE-AD) (-59.6% run-up) | Alzheimer's disease | Phase 1b | 8% |
| 2027 | PMN | PMN310 (PRECISE-AD) (-59.6% run-up) | Alzheimer's disease | Phase 1b | 8% |
| 2026-12 | CRIS | emavusertib (CA-4948) | Chronic Lymphocytic Leukemia (CLL) | Phase 2 | Low 🔒 |
| 2026-12-12 | SLS | tambiciclib (SLS009) in combination with azacitidine and venetoclax | Relapsed/Refractory Acute Myeloid Leukemia (r/r AML) | Phase 2 | Low 🔒 |
| 2026-11-18 | HUMA | Acellular Tissue Engineered Vessel (ATEV) | Hemodialysis access | Phase 3 | High 🔒 |
| 2026-12 | NRSN | PrimeC | amyotrophic lateral sclerosis (ALS) | NDA | Low 🔒 |
| 2026-11-18 | ACTU | Elraglusib Oral Tablet | B16F10 melanoma model | Pre-clinical | High 🔒 |
| 2026-11-22 | CAPR | Deramiocel (CAP-1002) | Duchenne muscular dystrophy (DMD) | PDUFA | High 🔒 |
| 2026-12-12 | APVO | mipletamig | frontline acute myeloid leukemia (AML), in combination with venetoclax and azacitidine, patients unfit for intensive chemotherapy | Phase 1b/2 | Low 🔒 |
Troculeucel (SNK01): An Investigational Approach to Alzheimer's Disease
Troculeucel, developed by NKGen Biotech, is an investigational NK cell therapy aimed at moderate Alzheimer's disease. The upcoming Phase 1 data presentation on November 16, 2026, is critical as it may validate the therapy's novel approach of using NK cells' immunomodulatory properties. With a probability of approval (PoA) at 3%, this reflects the high risks typical of early-stage therapies. The Phase 1/2a trial, SNK01-AD01, focuses on safety and exploratory efficacy, with 11 patients enrolled so far. Early findings indicate that 50% to 70% of subjects have shown stable or improved cognitive measures, and 90% maintained stable ADCOMS scores post-treatment. Yet, these results are based on small samples with no control group, raising questions about reliability. The lack of drug-related adverse events is encouraging, but the limited data leaves room for doubt about the therapy's long-term safety and efficacy. Without major partnerships or prior FDA interactions, Troculeucel's path is uncertain, making this event one to watch closely.
EYP-1901 (DURAVYU): Addressing the Burden of Wet AMD
The forthcoming Phase 3 data presentation for EYP-1901, branded as DURAVYU, is scheduled for December 3, 2026, marking a significant moment in treating wet age-related macular degeneration (AMD). With an 18% PoA, this bioerodible intravitreal insert seeks to deliver vorolanib, a multitarget tyrosine-kinase inhibitor, for up to six months. The global retinal anti-VEGF market is anticipated to hit $14 billion in 2024, highlighting the demand for a reliable, less burdensome treatment option as current therapies require frequent injections. EYP-1901's pivotal trials, LUGANO and LUCIA, aim to prove noninferiority to aflibercept, with results likely affecting its market stance. Still, the LUCIA trial's recent failure to meet its primary endpoint raises concerns about its commercial prospects. Despite no alarming safety signals, the absence of detailed enrollment and efficacy data puts approval at risk. If EYP-1901 overcomes these hurdles, it could redefine wet AMD treatment standards.
PMN310: A New Hope in Alzheimer's Disease Treatment
PMN310, an investigational IgG1 monoclonal antibody from ProMIS Neurosciences, is in Phase 1b trials for Alzheimer’s disease. The data presentation on November 16, 2026, is crucial, showcasing a unique mechanism that selectively targets toxic amyloid-beta oligomers. With an 8% PoA, the therapy faces significant challenges in proving clinical efficacy. The study, now with 144 participants, aims to offer insights into safety, tolerability, and preliminary efficacy. Interim findings showing no ARIA-E cases are promising, but success depends on demonstrating meaningful clinical benefits, especially against established therapies like lecanemab and donanemab. The unblinded results, expected in early 2027, will be vital in determining PMN310's future and its place in a projected $30 billion Alzheimer's market.
Upcoming Catalysts: A Look at the FDA Calendar
As 2026 wraps up, several biotech catalysts on the FDA calendar deserve attention. On November 22, 2026, CAPR will present data on Deramiocel (CAP-1002) for Duchenne muscular dystrophy (DMD), with a high PoA. This therapy could address a significant unmet need in a patient group with limited options. On December 3, 2026, EYPT's EYP-1901 data presentation will be crucial for wet AMD, while SLS will present tambiciclib with azacitidine and venetoclax for relapsed/refractory acute myeloid leukemia (AML) on December 12, 2026. These events highlight ongoing innovation in biotech and underscore the importance of timely data releases in shaping stock performance and investment choices.
Market Implications of Biotech Catalysts
The market implications of these biotech catalysts are significant, given the substantial unmet needs in Alzheimer’s disease and wet AMD. Approval of Troculeucel, EYP-1901, or PMN310 could reshape treatment approaches, potentially capturing large market shares in their respective fields. Investors should weigh approval probabilities and the competitive landscape when assessing these events. The Alzheimer's market alone is on track to hit $30 billion by the mid-2030s, while wet AMD therapies are vital in a $14 billion market. Clinical data, regulatory decisions, and market dynamics will play a crucial role in the commercial success of these therapies. Upcoming data presentations will be scrutinized for their scientific value and financial impact.
Navigating Risks in Biotech Investments
Investing in biotech is risky, with uncertainties around clinical trial outcomes and regulatory approvals. The current landscape shows many companies, including those mentioned, face hurdles in proving efficacy and safety. While Troculeucel and PMN310 have promising mechanisms, their lack of robust data raises viability questions. Similarly, EYP-1901's recent trial setbacks highlight the unpredictability of late-stage development. Investors should be mindful of these companies' cash runways, as five on our watchlist have less than a year of cash remaining. A complete response letter (CRL) could force financing at unfavorable terms, increasing risks. Understanding these dynamics is essential for informed investment decisions in biotech.
The bottom line
Critical data presentations are approaching, and staying informed is essential for investors navigating the biotech landscape.